企業プロフィール
UroGen Pharma 株価・ニュース・カタリスト
- ティッカー:
- URGN
- 取引所:
- NASDAQ
- セクター:
- Biopharma
- 所在地:
- Israel with U
株価パフォーマンス
49.14 USD (+1.91%)
終値
最終更新: 2026年8月17日
1.29B USD
時価総額
株価変動の要因
The latest company update was “UroGen Submits NDA for UGN-103, an Investigational Treatment of Recurrent LG-IR-NMIBC”. URGN changed 1.91% and closed at $49.14 on Aug 17, 2026, indicating a relatively limited closing-price reaction to this company update.
企業概要
Uro-Oncology Franchise
UroGen Pharma develops and commercializes treatments for urothelial and other specialty cancers. Its approach combines local drug delivery with formulations intended to extend exposure within the urinary tract and provide non-surgical alternatives for patients with recurrent disease.
Commercial ZUSDURI Platform
ZUSDURI is FDA approved for adults with recurrent low-grade, intermediate-risk non-muscle invasive bladder cancer. The intravesical mitomycin product uses UroGen’s RTGel technology and anchors the company’s commercial presence in bladder cancer.
Next-Generation Mitomycin Programs
UGN-103 is a next-generation mitomycin formulation for recurrent low-grade intermediate-risk NMIBC and is advancing toward an NDA based on the Phase 3 UTOPIA trial. UGN-104 applies a related formulation strategy to low-grade upper tract urothelial carcinoma and is being studied in an ongoing Phase 3 trial.
Oncolytic Virus Expansion
UGN-501 is an investigational next-generation oncolytic virus initially planned for intravesical administration in NMIBC. The company also intends to evaluate delivery with RTGel, potentially extending local exposure and activity.
今後のカタリスト
- Six-month durability data for UGN-103 expected in mid-2026.
- UGN-501 IND submission planned for the second quarter of 2026, followed by Phase 1 initiation by year-end.
- UGN-103 NDA submission planned for the second half of 2026.
- Completion of enrollment in the UGN-104 Phase 3 trial expected by year-end 2026.
最近のニュース
- 01
- 02
- 03
- 04
- 05
類似銘柄
事業成熟度、治療領域、カタリスト傾向が近い同業銘柄です。